Skip to main content
. 2021 Jan 22;7(4):eabd9502. doi: 10.1126/sciadv.abd9502

Fig. 5. JAK inhibitors prevent IFN-γ–induced deficits in myobundle force generation and structural organization.

Fig. 5

(A) Schematic overview of myobundle culture, treatment, and characterization. Human primary myoblasts were expanded in 2D culture and mixed with hydrogel to form 3D myobundles, which were cultured in GM for 4 days, then in DM for 6 days, after which JAK inhibitors (JAKi) tofacitinib (Tofa, 500 nM) or baricitinib (Bari, 500 nM) was applied for additional 8 days, the last 7 of which in the presence or absence of IFN-γ. (B) Contractile force amplitude per myobundle CSA (specific force, n = 11 to 15 myobundles from three donors per group). (C) Quantified CSA of myobundles. (D) Quantified myotube diameter from myobundle cross sections (n ≥ 720 myotubes from three donors per group). (E and F) Quantified (E) projected myotube length (n > 150 myotubes from two donors per group) and (F) SAA cross-striation frequency (n ≥ 30 images from three donors per group) from longitudinal sections of myobundles. *P < 0.05 versus IFN-γ−, #P < 0.05 versus IFN-γ+. NS, nonsignificant. Data are presented as means ± SEM.